Lucile Astorgues‐Xerri
Inserm(FR)Saint Louis University Hospital(US)Institut National de Recherche en Santé Publique(ML)Assistance Publique – Hôpitaux de Paris(FR)
Publications by Year
Research Areas
Protein Degradation and Inhibitors, Multiple Myeloma Research and Treatments, CAR-T cell therapy research, Galectins and Cancer Biology, Ubiquitin and proteasome pathways
Most-Cited Works
- → Unraveling galectin-1 as a novel therapeutic target for cancer(2013)214 cited
- → Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition(2015)178 cited
- → OTX015 (MK‐8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models(2016)150 cited
- → OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis(2014)134 cited
- → Antitumor Agent Calixarene 0118 Targets Human Galectin-1 as an Allosteric Inhibitor of Carbohydrate Binding(2012)130 cited
- → Macrophages in the microenvironment of head and neck cancer: potential targets for cancer therapy(2018)97 cited